Description
BLOOD BANK REAGENTS
First action · last action
2020-06-02 · 2025-04-23
Transactions
7
First transaction's obligation
$49,816
Base + all options value (sum of deltas)
$45,408
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
—
SDVOSB flag on record
No
Parent IDV
36C25520A0034
NAICS
325413 · IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING
Modification chain · 7 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2020-06-02+$49,816= $49,816
- Mod P000012021-03-30+$2,344= $52,160
- Mod P000022021-04-16+$1,500= $53,660
- Mod P000032023-12-19-$17,267= $36,393
- Mod P000042024-07-05-$360= $36,033
- Mod P000052024-11-13-$4,520= $31,514
- Mod P000062025-04-23-$3,926= $27,588
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2020-06-02 | +$49,816 | $49,816 | BLOOD BANK REAGENTS |
| Mod P00001· FUNDING ONLY ACTION | 2021-03-30 | +$2,344 | $52,160 | BLOOD BANK REAGENTS |
| Mod P00002· FUNDING ONLY ACTION | 2021-04-16 | +$1,500 | $53,660 | BLOOD BANK REAGENTS |
| Mod P00003· FUNDING ONLY ACTION | 2023-12-19 | −$17,267 | $36,393 | BLOOD BANK REAGENTS |
| Mod P00004· FUNDING ONLY ACTION | 2024-07-05 | −$360 | $36,033 | BLOOD BANK REAGENTS |
| Mod P00005· FUNDING ONLY ACTION | 2024-11-13 | −$4,520 | $31,514 | BLOOD BANK REAGENTS |
| Mod P00006· FUNDING ONLY ACTION | 2025-04-23 | −$3,926 | $27,588 | BLOOD BANK REAGENTS |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI V6KNKL6BDHL7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25526N0306 | 255-NETWORK CONTRACT OFFICE 15 (36C255) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $40,949 | FY2026 |
| 36C25926N0280 | NETWORK CONTRACT OFFICE 19 (36C259) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $64,078 | FY2026 |
| 36C25726N0176 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6505 · DRUGS AND BIOLOGICALS | $7,634 | FY2026 |
| 36C25726N0224 | 257-NETWORK CONTRACT OFFICE 17 (36C257) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $16,514 | FY2026 |
| 36C25626N0214 | 256-NETWORK CONTRACT OFFICE 16 (36C256) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $23,127 | FY2026 |
| 36C25026N0043 | 250-NETWORK CONTRACT OFFICE 10 (36C250) · 6550 · IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS | $21,884 | FY2026 |
Other recipients under 6550 from 255-NETWORK CONTRACT OFFICE 15 (36C255) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C25526N0405 | FISHER SCIENTIFIC COMPANY L.L.C. | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $113,611 | FY2026 |
| 36C25526N0337 | CEPHEID | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $2,571,141 | FY2026 |
| 36C25526N0307 | WERFEN USA LLC | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $76,810 | FY2026 |
| 36C25526N0312 | QUIDELORTHO SALES COMPANY, LLC | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $21,363 | FY2026 |
| 36C25526A0030 | QUIDELORTHO SALES COMPANY, LLC | 255-NETWORK CONTRACT OFFICE 15 (36C255) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C25520N0287_3600_36C25520A0034_3600 · retrieved 2026-09-26.